6/24/26 – Based on data from CORE – TIMI 72a and CORE2 – TIMI 72b, the FDA has approved olezarsen, an antisense oligonucleotide that inhibits the production of apolipoprotein C-III, to reduce triglycerides and risk of acute pancreatitis in adults with severe hypertriglyceridemia. 3/18/26 – TIMI Chairman Dr. Marc Sabatine invited to give Medicine Grand … Continue reading News